TB-500 Australia: Schedule 4, Human Evidence, FDA Review and WADA Rules

Why the naming distinction matters

Search results often collapse thymosin beta-4, TB-500 and “healing peptides” into one concept. That can make evidence for a full-length biological protein appear to support a shorter marketed fragment. Chemical form, sequence, formulation and route influence pharmacology, stability and immunogenicity. Evidence must match the actual material being discussed.

For context, compare our BPC-157 Australian evidence guide, the 2026 peptide anti-doping map, and the FDA peptide compounding safety review. These sources address different questions; none establishes that a product advertised as a “healing stack” is safe or effective.

Australian regulatory status

The October 2026 Poisons Standard names TB-500 and thymosin beta-4 in Schedule 4 and Appendix D, clause 5, at items 38 and 39 respectively. Regulatory source checked: 22 October 2026. Schedule 4 is a prescription-only classification, and Appendix D adds controls on possession without authority. Scheduling is not product registration or proof that tendon, ligament or muscle repair claims work. The TGA’s August 2026 enforcement release also named a so-called “Wolverine Stack” combining BPC-157 and TB-500 among allegedly imported, relabelled and advertised products.

What has the FDA reviewed?

In July 2026, the FDA Pharmacy Compounding Advisory Committee considered TB-500-related bulk substances nominated for wound healing. A nomination or committee discussion is not approval. FDA’s safety-risk page states that compounded products containing the thymosin beta-4 fragment may pose immunogenicity risk because of aggregation and peptide-related impurities, and that the agency lacks enough information to know whether it would cause harm in humans.

How strong is the human evidence?

A trustworthy review separates evidence about native thymosin beta-4 from evidence about the marketed TB-500 fragment. Laboratory and animal findings may justify research questions, but they cannot establish recovery time, return-to-sport, long-term safety or an appropriate therapeutic use in people. Claims such as “systemic healing” are especially broad and should trigger a search for defined populations and outcomes.

Questions to ask when reading a claim

• Was the tested molecule full-length thymosin beta-4 or the TB-500 fragment?
• Was the study performed in cells, animals or humans?
• Were function and adverse events measured, or only a surrogate marker?
• Was the product chemically characterised and independently verified?
• Does the regulatory statement describe scheduling, registration, compounding policy or anti-doping rules?

Common questions

Primary sources

1. Australian Poisons Standard—October 2026: TB-500 and thymosin beta-4 in Schedule 4 and Appendix D, clause 5
2. TGA August 2026 enforcement release: unapproved products and the “Wolverine Stack”
3. FDA peptide compounding safety-risk table
4. FDA July 2026 advisory committee materials
5. WADA 2026 Prohibited List